Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-1,100
Closed -$1K 671
2019
Q2
$1K Hold
1,100
﹤0.01% 553
2019
Q1
$1K Buy
+1,100
New +$210K ﹤0.01% 527
2016
Q3
Sell
-1,100
Closed -$2K 550
2016
Q2
$2K Buy
+1,100
New +$171K ﹤0.01% 517
2016
Q1
Sell
-1,100
Closed -$2K 524
2015
Q4
$2K Buy
+1,100
New +$173K ﹤0.01% 514

Other funds holding AMGN

Moors & Cabot's AMGN Position: Q2 2026 in Review

Moors & Cabot reduced its Amgen (AMGN) stake by 0.94% in Q2 2026, selling an estimated $48.3K and leaving 14,884 shares worth $5.39M. The position accounts for 0.21% of the portfolio, ranked #96.

Moors & Cabot first reported a position in AMGN in Q1 2014 and has held it in 50 quarters since. The position peaked at $7.4M in Q4 2019. 3,157 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Moors & Cabot held 14,884 shares of Amgen worth $5.39M as of Q2 2026.
  • Moors & Cabot sold 141 Amgen shares in Q2 2026, an estimated $48.3K.
  • Amgen made up 0.21% of Moors & Cabot's portfolio in Q2 2026, its #96 holding.
  • Moors & Cabot first reported a position in Amgen in Q1 2014 and has held it in 50 quarters since.
  • Moors & Cabot's Amgen position peaked at $7.4M in Q4 2019.
  • 3,157 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.